table of content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.4.1 North America Market States and Outlook (2023-2028)
1.4.2 East Asia Market States and Outlook (2023-2028)
1.4.3 Europe Market States and Outlook (2023-2028)
1.4.4 South Asia Market States and Outlook (2023-2028)
1.4.5 Southeast Asia Market States and Outlook (2023-2028)
1.4.6 Middle East Market States and Outlook (2023-2028)
1.4.7 Africa Market States and Outlook (2023-2028)
1.4.8 Oceania Market States and Outlook (2023-2028)
1.4.9 South America Market States and Outlook (2023-2028)
1.5 Global Direct-acting Antiviral Drugs Market Size Analysis from 2023 to 2028
1.5.1 Global Direct-acting Antiviral Drugs Market Size Analysis from 2023 to 2028 by Consumption Volume
1.5.2 Global Direct-acting Antiviral Drugs Market Size Analysis from 2023 to 2028 by Value
1.5.3 Global Direct-acting Antiviral Drugs Price Trends Analysis from 2023 to 2028
1.6 COVID-19 Outbreak: Direct-acting Antiviral Drugs Industry Impact
Chapter 2 Global Direct-acting Antiviral Drugs Competition by Types, Applications, and Top Regions and Countries
2.1 Global Direct-acting Antiviral Drugs (Volume and Value) by Type
2.1.1 Global Direct-acting Antiviral Drugs Consumption and Market Share by Type (2017-2022)
2.1.2 Global Direct-acting Antiviral Drugs Revenue and Market Share by Type (2017-2022)
2.2 Global Direct-acting Antiviral Drugs (Volume and Value) by Application
2.2.1 Global Direct-acting Antiviral Drugs Consumption and Market Share by Application (2017-2022)
2.2.2 Global Direct-acting Antiviral Drugs Revenue and Market Share by Application (2017-2022)
2.3 Global Direct-acting Antiviral Drugs (Volume and Value) by Regions
2.3.1 Global Direct-acting Antiviral Drugs Consumption and Market Share by Regions (2017-2022)
2.3.2 Global Direct-acting Antiviral Drugs Revenue and Market Share by Regions (2017-2022)
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.1.1 2017-2022 Global Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis
3.1.2 2017-2022 Major Manufacturers Performance and Market Share
3.2 Regional Production Market Analysis
3.2.1 2017-2022 Regional Market Performance and Market Share
3.2.2 North America Market
3.2.3 East Asia Market
3.2.4 Europe Market
3.2.5 South Asia Market
3.2.6 Southeast Asia Market
3.2.7 Middle East Market
3.2.8 Africa Market
3.2.9 Oceania Market
3.2.10 South America Market
3.2.11 Rest of the World Market
Chapter 4 Global Direct-acting Antiviral Drugs Sales, Consumption, Export, Import by Regions (2017-2022)
4.1 Global Direct-acting Antiviral Drugs Consumption by Regions (2017-2022)
4.2 North America Direct-acting Antiviral Drugs Sales, Consumption, Export, Import (2017-2022)
4.3 East Asia Direct-acting Antiviral Drugs Sales, Consumption, Export, Import (2017-2022)
4.4 Europe Direct-acting Antiviral Drugs Sales, Consumption, Export, Import (2017-2022)
4.5 South Asia Direct-acting Antiviral Drugs Sales, Consumption, Export, Import (2017-2022)
4.6 Southeast Asia Direct-acting Antiviral Drugs Sales, Consumption, Export, Import (2017-2022)
4.7 Middle East Direct-acting Antiviral Drugs Sales, Consumption, Export, Import (2017-2022)
4.8 Africa Direct-acting Antiviral Drugs Sales, Consumption, Export, Import (2017-2022)
4.9 Oceania Direct-acting Antiviral Drugs Sales, Consumption, Export, Import (2017-2022)
4.10 South America Direct-acting Antiviral Drugs Sales, Consumption, Export, Import (2017-2022)
Chapter 5 North America Direct-acting Antiviral Drugs Market Analysis
5.1 North America Direct-acting Antiviral Drugs Consumption and Value Analysis
5.1.1 North America Direct-acting Antiviral Drugs Market Under COVID-19
5.2 North America Direct-acting Antiviral Drugs Consumption Volume by Types
5.3 North America Direct-acting Antiviral Drugs Consumption Structure by Application
5.4 North America Direct-acting Antiviral Drugs Consumption by Top Countries
5.4.1 United States Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
5.4.2 Canada Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
5.4.3 Mexico Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
Chapter 6 East Asia Direct-acting Antiviral Drugs Market Analysis
6.1 East Asia Direct-acting Antiviral Drugs Consumption and Value Analysis
6.1.1 East Asia Direct-acting Antiviral Drugs Market Under COVID-19
6.2 East Asia Direct-acting Antiviral Drugs Consumption Volume by Types
6.3 East Asia Direct-acting Antiviral Drugs Consumption Structure by Application
6.4 East Asia Direct-acting Antiviral Drugs Consumption by Top Countries
6.4.1 China Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
6.4.2 Japan Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
6.4.3 South Korea Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
Chapter 7 Europe Direct-acting Antiviral Drugs Market Analysis
7.1 Europe Direct-acting Antiviral Drugs Consumption and Value Analysis
7.1.1 Europe Direct-acting Antiviral Drugs Market Under COVID-19
7.2 Europe Direct-acting Antiviral Drugs Consumption Volume by Types
7.3 Europe Direct-acting Antiviral Drugs Consumption Structure by Application
7.4 Europe Direct-acting Antiviral Drugs Consumption by Top Countries
7.4.1 Germany Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
7.4.2 UK Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
7.4.3 France Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
7.4.4 Italy Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
7.4.5 Russia Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
7.4.6 Spain Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
7.4.7 Netherlands Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
7.4.8 Switzerland Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
7.4.9 Poland Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
Chapter 8 South Asia Direct-acting Antiviral Drugs Market Analysis
8.1 South Asia Direct-acting Antiviral Drugs Consumption and Value Analysis
8.1.1 South Asia Direct-acting Antiviral Drugs Market Under COVID-19
8.2 South Asia Direct-acting Antiviral Drugs Consumption Volume by Types
8.3 South Asia Direct-acting Antiviral Drugs Consumption Structure by Application
8.4 South Asia Direct-acting Antiviral Drugs Consumption by Top Countries
8.4.1 India Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
8.4.2 Pakistan Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
8.4.3 Bangladesh Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
Chapter 9 Southeast Asia Direct-acting Antiviral Drugs Market Analysis
9.1 Southeast Asia Direct-acting Antiviral Drugs Consumption and Value Analysis
9.1.1 Southeast Asia Direct-acting Antiviral Drugs Market Under COVID-19
9.2 Southeast Asia Direct-acting Antiviral Drugs Consumption Volume by Types
9.3 Southeast Asia Direct-acting Antiviral Drugs Consumption Structure by Application
9.4 Southeast Asia Direct-acting Antiviral Drugs Consumption by Top Countries
9.4.1 Indonesia Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
9.4.2 Thailand Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
9.4.3 Singapore Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
9.4.4 Malaysia Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
9.4.5 Philippines Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
9.4.6 Vietnam Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
9.4.7 Myanmar Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
Chapter 10 Middle East Direct-acting Antiviral Drugs Market Analysis
10.1 Middle East Direct-acting Antiviral Drugs Consumption and Value Analysis
10.1.1 Middle East Direct-acting Antiviral Drugs Market Under COVID-19
10.2 Middle East Direct-acting Antiviral Drugs Consumption Volume by Types
10.3 Middle East Direct-acting Antiviral Drugs Consumption Structure by Application
10.4 Middle East Direct-acting Antiviral Drugs Consumption by Top Countries
10.4.1 Turkey Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
10.4.2 Saudi Arabia Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
10.4.3 Iran Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
10.4.4 United Arab Emirates Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
10.4.5 Israel Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
10.4.6 Iraq Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
10.4.7 Qatar Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
10.4.8 Kuwait Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
10.4.9 Oman Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
Chapter 11 Africa Direct-acting Antiviral Drugs Market Analysis
11.1 Africa Direct-acting Antiviral Drugs Consumption and Value Analysis
11.1.1 Africa Direct-acting Antiviral Drugs Market Under COVID-19
11.2 Africa Direct-acting Antiviral Drugs Consumption Volume by Types
11.3 Africa Direct-acting Antiviral Drugs Consumption Structure by Application
11.4 Africa Direct-acting Antiviral Drugs Consumption by Top Countries
11.4.1 Nigeria Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
11.4.2 South Africa Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
11.4.3 Egypt Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
11.4.4 Algeria Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
11.4.5 Morocco Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
Chapter 12 Oceania Direct-acting Antiviral Drugs Market Analysis
12.1 Oceania Direct-acting Antiviral Drugs Consumption and Value Analysis
12.2 Oceania Direct-acting Antiviral Drugs Consumption Volume by Types
12.3 Oceania Direct-acting Antiviral Drugs Consumption Structure by Application
12.4 Oceania Direct-acting Antiviral Drugs Consumption by Top Countries
12.4.1 Australia Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
12.4.2 New Zealand Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
Chapter 13 South America Direct-acting Antiviral Drugs Market Analysis
13.1 South America Direct-acting Antiviral Drugs Consumption and Value Analysis
13.1.1 South America Direct-acting Antiviral Drugs Market Under COVID-19
13.2 South America Direct-acting Antiviral Drugs Consumption Volume by Types
13.3 South America Direct-acting Antiviral Drugs Consumption Structure by Application
13.4 South America Direct-acting Antiviral Drugs Consumption Volume by Major Countries
13.4.1 Brazil Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
13.4.2 Argentina Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
13.4.3 Columbia Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
13.4.4 Chile Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
13.4.5 Venezuela Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
13.4.6 Peru Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
13.4.7 Puerto Rico Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
13.4.8 Ecuador Direct-acting Antiviral Drugs Consumption Volume from 2017 to 2022
Chapter 14 Company Profiles and Key Figures in Direct-acting Antiviral Drugs Business
14.1 AbbVie Inc.
14.1.1 AbbVie Inc. Company Profile
14.1.2 AbbVie Inc. Direct-acting Antiviral Drugs Product Specification
14.1.3 AbbVie Inc. Direct-acting Antiviral Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.2 Bristol-Myers Squibb Company
14.2.1 Bristol-Myers Squibb Company Company Profile
14.2.2 Bristol-Myers Squibb Company Direct-acting Antiviral Drugs Product Specification
14.2.3 Bristol-Myers Squibb Company Direct-acting Antiviral Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.3 Merck
14.3.1 Merck Company Profile
14.3.2 Merck Direct-acting Antiviral Drugs Product Specification
14.3.3 Merck Direct-acting Antiviral Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.4 GSK
14.4.1 GSK Company Profile
14.4.2 GSK Direct-acting Antiviral Drugs Product Specification
14.4.3 GSK Direct-acting Antiviral Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.5 Roche
14.5.1 Roche Company Profile
14.5.2 Roche Direct-acting Antiviral Drugs Product Specification
14.5.3 Roche Direct-acting Antiviral Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.6 Boehringer Ingelheim
14.6.1 Boehringer Ingelheim Company Profile
14.6.2 Boehringer Ingelheim Direct-acting Antiviral Drugs Product Specification
14.6.3 Boehringer Ingelheim Direct-acting Antiviral Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.7 Janssen (Johnson & Johnson)
14.7.1 Janssen (Johnson & Johnson) Company Profile
14.7.2 Janssen (Johnson & Johnson) Direct-acting Antiviral Drugs Product Specification
14.7.3 Janssen (Johnson & Johnson) Direct-acting Antiviral Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.8 Beximco Pharmaceuticals
14.8.1 Beximco Pharmaceuticals Company Profile
14.8.2 Beximco Pharmaceuticals Direct-acting Antiviral Drugs Product Specification
14.8.3 Beximco Pharmaceuticals Direct-acting Antiviral Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.9 Novartis
14.9.1 Novartis Company Profile
14.9.2 Novartis Direct-acting Antiviral Drugs Product Specification
14.9.3 Novartis Direct-acting Antiviral Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.10 Gilead Sciences
14.10.1 Gilead Sciences Company Profile
14.10.2 Gilead Sciences Direct-acting Antiviral Drugs Product Specification
14.10.3 Gilead Sciences Direct-acting Antiviral Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.11 Vertex Pharmaceuticals
14.11.1 Vertex Pharmaceuticals Company Profile
14.11.2 Vertex Pharmaceuticals Direct-acting Antiviral Drugs Product Specification
14.11.3 Vertex Pharmaceuticals Direct-acting Antiviral Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.12 Natco Pharma
14.12.1 Natco Pharma Company Profile
14.12.2 Natco Pharma Direct-acting Antiviral Drugs Product Specification
14.12.3 Natco Pharma Direct-acting Antiviral Drugs Production Capacity, Revenue, Price and Gross Margin (2017-2022)
Chapter 15 Global Direct-acting Antiviral Drugs Market Forecast (2023-2028)
15.1 Global Direct-acting Antiviral Drugs Consumption Volume, Revenue and Price Forecast (2023-2028)
15.1.1 Global Direct-acting Antiviral Drugs Consumption Volume and Growth Rate Forecast (2023-2028)
15.1.2 Global Direct-acting Antiviral Drugs Value and Growth Rate Forecast (2023-2028)
15.2 Global Direct-acting Antiviral Drugs Consumption Volume, Value and Growth Rate Forecast by Region (2023-2028)
15.2.1 Global Direct-acting Antiviral Drugs Consumption Volume and Growth Rate Forecast by Regions (2023-2028)
15.2.2 Global Direct-acting Antiviral Drugs Value and Growth Rate Forecast by Regions (2023-2028)
15.2.3 North America Direct-acting Antiviral Drugs Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.4 East Asia Direct-acting Antiviral Drugs Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.5 Europe Direct-acting Antiviral Drugs Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.6 South Asia Direct-acting Antiviral Drugs Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.7 Southeast Asia Direct-acting Antiviral Drugs Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.8 Middle East Direct-acting Antiviral Drugs Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.9 Africa Direct-acting Antiviral Drugs Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.10 Oceania Direct-acting Antiviral Drugs Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.11 South America Direct-acting Antiviral Drugs Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.3 Global Direct-acting Antiviral Drugs Consumption Volume, Revenue and Price Forecast by Type (2023-2028)
15.3.1 Global Direct-acting Antiviral Drugs Consumption Forecast by Type (2023-2028)
15.3.2 Global Direct-acting Antiviral Drugs Revenue Forecast by Type (2023-2028)
15.3.3 Global Direct-acting Antiviral Drugs Price Forecast by Type (2023-2028)
15.4 Global Direct-acting Antiviral Drugs Consumption Volume Forecast by Application (2023-2028)
15.5 Direct-acting Antiviral Drugs Market Forecast Under COVID-19
Chapter 16 Conclusions
Research Methodology
